Skip to main content
Top
Published in: Diabetologia 2/2017

Open Access 01-02-2017 | Article

ADAMTS13 activity as a novel risk factor for incident type 2 diabetes mellitus: a population-based cohort study

Authors: Paul S. de Vries, Thijs T. W. van Herpt, Symen Ligthart, Albert Hofman, M. Arfan Ikram, Mandy van Hoek, Eric J. G. Sijbrands, Oscar H. Franco, Moniek P. M. de Maat, Frank W. G. Leebeek, Abbas Dehghan

Published in: Diabetologia | Issue 2/2017

Login to get access

Abstract

Aims/hypothesis

ADAMTS13 is a protease that breaks down von Willebrand factor (VWF) multimers into smaller, less active particles. VWF has been associated with an increased risk of incident type 2 diabetes mellitus. Here, we determine whether ADAMTS13 activity and VWF antigen are associated with incident diabetes.

Methods

This study included 5176 participants from the Rotterdam Study, a prospective population-based cohort study. Participants were free of diabetes at baseline and followed up for more than 20 years. Cox proportional hazards models were used to examine the association of ADAMTS13 activity and VWF antigen with incident diabetes.

Results

ADAMTS13 activity was associated with an increased risk of incident diabetes (HR 1.17 [95% CI 1.08, 1.27]) after adjustment for known risk factors and VWF antigen levels. Although ADAMTS13 activity was positively associated with fasting glucose and insulin, the association with incident diabetes did not change when we adjusted for these covariates. ADAMTS13 activity was also associated with incident prediabetes (defined on the basis of both fasting and non-fasting blood glucose) after adjustment for known risk factors (HR 1.11 [95% CI 1.03, 1.19]), while the VWF antigen level was not. VWF antigen was associated with incident diabetes, but this association was attenuated after adjustment for known risk factors.

Conclusions/interpretation

ADAMTS13 activity appears to be an independent risk factor for incident prediabetes and type 2 diabetes. As the association between ADAMTS13 and diabetes did not appear to be explained by its cleavage of VWF, ADAMTS13 may have an independent role in the development of diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fujikawa K, Suzuki H, McMullen B, Chung D (2001) Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98:1662–1666CrossRefPubMed Fujikawa K, Suzuki H, McMullen B, Chung D (2001) Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98:1662–1666CrossRefPubMed
2.
go back to reference Gerritsen HE, Robles R, Lammle B, Furlan M (2001) Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 98:1654–1661CrossRefPubMed Gerritsen HE, Robles R, Lammle B, Furlan M (2001) Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 98:1654–1661CrossRefPubMed
3.
go back to reference Andersson HM, Siegerink B, Luken BM et al (2012) High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood 119:1555–1560CrossRefPubMed Andersson HM, Siegerink B, Luken BM et al (2012) High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood 119:1555–1560CrossRefPubMed
4.
go back to reference Bongers TN, de Bruijne EL, Dippel DW et al (2009) Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis 207:250–254CrossRefPubMed Bongers TN, de Bruijne EL, Dippel DW et al (2009) Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis 207:250–254CrossRefPubMed
5.
go back to reference Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR (2007) ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 109:1998–2000CrossRefPubMed Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR (2007) ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 109:1998–2000CrossRefPubMed
6.
go back to reference Crawley JT, Lane DA, Woodward M, Rumley A, Lowe GD (2008) Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost 6:583–588CrossRefPubMedPubMedCentral Crawley JT, Lane DA, Woodward M, Rumley A, Lowe GD (2008) Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost 6:583–588CrossRefPubMedPubMedCentral
7.
go back to reference Sonneveld MA, de Maat MP, Leebeek FW (2014) Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev 28:167–178CrossRefPubMed Sonneveld MA, de Maat MP, Leebeek FW (2014) Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev 28:167–178CrossRefPubMed
8.
go back to reference Sonneveld MAH, de Maat MPM, Portegies MLP et al (2014) Low ADAMTS13 activity is a strong risk factor for ischemic stroke: a prospective cohort study - the Rotterdam Study. In: ASH Annual Meeting and Exposition, San Francisco, CA, USA Sonneveld MAH, de Maat MPM, Portegies MLP et al (2014) Low ADAMTS13 activity is a strong risk factor for ischemic stroke: a prospective cohort study - the Rotterdam Study. In: ASH Annual Meeting and Exposition, San Francisco, CA, USA
9.
go back to reference Sedaghat S, de Vries PS, Boender J et al (2016) von Willebrand factor, ADAMTS13 activity, and decline in kidney function: a population-based cohort study. Am J Kidney Dis Sedaghat S, de Vries PS, Boender J et al (2016) von Willebrand factor, ADAMTS13 activity, and decline in kidney function: a population-based cohort study. Am J Kidney Dis
11.
go back to reference Rurali E, Noris M, Chianca A et al (2013) ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy. Diabetes 62:3599–3609CrossRefPubMedPubMedCentral Rurali E, Noris M, Chianca A et al (2013) ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy. Diabetes 62:3599–3609CrossRefPubMedPubMedCentral
12.
go back to reference Taniguchi S, Hashiguchi T, Ono T et al (2010) Association between reduced ADAMTS13 and diabetic nephropathy. Thromb Res 125:e310–e316CrossRefPubMed Taniguchi S, Hashiguchi T, Ono T et al (2010) Association between reduced ADAMTS13 and diabetic nephropathy. Thromb Res 125:e310–e316CrossRefPubMed
13.
go back to reference Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G (1999) Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 22:767–772CrossRefPubMed Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G (1999) Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 22:767–772CrossRefPubMed
14.
go back to reference Meigs JB, O’Donnell CJ, Tofler GH et al (2006) Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 55:530–537CrossRefPubMed Meigs JB, O’Donnell CJ, Tofler GH et al (2006) Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 55:530–537CrossRefPubMed
15.
go back to reference Muris DM, Houben AJ, Schram MT, Stehouwer CD (2012) Microvascular dysfunction is associated with a higher incidence of type 2 diabetes mellitus: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 32:3082–3094CrossRefPubMed Muris DM, Houben AJ, Schram MT, Stehouwer CD (2012) Microvascular dysfunction is associated with a higher incidence of type 2 diabetes mellitus: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 32:3082–3094CrossRefPubMed
16.
go back to reference Thorand B, Baumert J, Chambless L et al (2006) Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 26:398–405CrossRefPubMed Thorand B, Baumert J, Chambless L et al (2006) Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 26:398–405CrossRefPubMed
17.
go back to reference Wannamethee SG, Sattar N, Rumley A, Whincup PH, Lennon L, Lowe GD (2008) Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men. Diabetes Care 31:995–1000CrossRefPubMed Wannamethee SG, Sattar N, Rumley A, Whincup PH, Lennon L, Lowe GD (2008) Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men. Diabetes Care 31:995–1000CrossRefPubMed
18.
go back to reference Mannucci PM (1998) von Willebrand factor: a marker of endothelial damage? Arterioscler Thromb Vasc Biol 18:1359–1362CrossRefPubMed Mannucci PM (1998) von Willebrand factor: a marker of endothelial damage? Arterioscler Thromb Vasc Biol 18:1359–1362CrossRefPubMed
19.
20.
go back to reference Jaap AJ, Shore AC, Tooke JE (1997) Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycaemia. Diabetologia 40:238–243CrossRefPubMed Jaap AJ, Shore AC, Tooke JE (1997) Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycaemia. Diabetologia 40:238–243CrossRefPubMed
21.
go back to reference Tal MG (2009) Type 2 diabetes: Microvascular ischemia of pancreatic islets? Med Hypotheses 73:357–358CrossRefPubMed Tal MG (2009) Type 2 diabetes: Microvascular ischemia of pancreatic islets? Med Hypotheses 73:357–358CrossRefPubMed
22.
go back to reference Tooke JE (1995) Microvascular function in human diabetes. A physiological perspective. Diabetes 44:721–726CrossRefPubMed Tooke JE (1995) Microvascular function in human diabetes. A physiological perspective. Diabetes 44:721–726CrossRefPubMed
23.
go back to reference de Vries PS, Boender J, Sonneveld MA et al (2015) Genetic variants in the ADAMTS13 and SUPT3H genes are associated with ADAMTS13 activity. Blood 125:3949–3955CrossRefPubMed de Vries PS, Boender J, Sonneveld MA et al (2015) Genetic variants in the ADAMTS13 and SUPT3H genes are associated with ADAMTS13 activity. Blood 125:3949–3955CrossRefPubMed
25.
go back to reference WHO, International Diabetes Federation (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. World Health Organization, Geneva WHO, International Diabetes Federation (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. World Health Organization, Geneva
26.
go back to reference Ligthart S, van Herpt TT, Leening MJ et al (2016) Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol 4:44–51CrossRefPubMed Ligthart S, van Herpt TT, Leening MJ et al (2016) Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol 4:44–51CrossRefPubMed
27.
go back to reference Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129:93–100CrossRefPubMed Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129:93–100CrossRefPubMed
28.
go back to reference Wieberdink RG, van Schie MC, Koudstaal PJ et al (2010) High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke 41:2151–2156CrossRefPubMed Wieberdink RG, van Schie MC, Koudstaal PJ et al (2010) High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke 41:2151–2156CrossRefPubMed
29.
go back to reference Neeley WE (1972) Simple automated determination of serum or plasma glucose by a hexokinase-glucose-6 -phosphate dehydrogenase method. Clin Chem 18:509–515PubMed Neeley WE (1972) Simple automated determination of serum or plasma glucose by a hexokinase-glucose-6 -phosphate dehydrogenase method. Clin Chem 18:509–515PubMed
30.
go back to reference Leening MJ, Kavousi M, Heeringa J et al (2012) Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study. Eur J Epidemiol 27:173–185CrossRefPubMedPubMedCentral Leening MJ, Kavousi M, Heeringa J et al (2012) Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study. Eur J Epidemiol 27:173–185CrossRefPubMedPubMedCentral
31.
go back to reference Sonneveld MA, de Maat MP, Portegies ML et al (2015) Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood 126:2739–2746CrossRefPubMed Sonneveld MA, de Maat MP, Portegies ML et al (2015) Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood 126:2739–2746CrossRefPubMed
32.
go back to reference Klein OL, Okwuosa T, Chan C et al (2014) Changes in procoagulants track longitudinally with insulin resistance: findings from the coronary artery risk development in young adults (CARDIA) study. Diabet Med 31:462–465CrossRefPubMedPubMedCentral Klein OL, Okwuosa T, Chan C et al (2014) Changes in procoagulants track longitudinally with insulin resistance: findings from the coronary artery risk development in young adults (CARDIA) study. Diabet Med 31:462–465CrossRefPubMedPubMedCentral
34.
go back to reference South K, Freitas MO, Lane DA (2016) Conformational quiescence of ADAMTS13 prevents proteolytic promiscuity. J Thromb Haemost doi: 10.1111/jth.13445 South K, Freitas MO, Lane DA (2016) Conformational quiescence of ADAMTS13 prevents proteolytic promiscuity. J Thromb Haemost doi: 10.​1111/​jth.​13445
35.
go back to reference Lee M, Keener J, Xiao J, Long Zheng X, Rodgers GM (2015) ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2. Cell Mol Life Sci 72:349–356CrossRefPubMed Lee M, Keener J, Xiao J, Long Zheng X, Rodgers GM (2015) ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2. Cell Mol Life Sci 72:349–356CrossRefPubMed
36.
go back to reference Hagberg CE, Mehlem A, Falkevall A et al (2012) Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 490:426–430CrossRefPubMed Hagberg CE, Mehlem A, Falkevall A et al (2012) Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 490:426–430CrossRefPubMed
Metadata
Title
ADAMTS13 activity as a novel risk factor for incident type 2 diabetes mellitus: a population-based cohort study
Authors
Paul S. de Vries
Thijs T. W. van Herpt
Symen Ligthart
Albert Hofman
M. Arfan Ikram
Mandy van Hoek
Eric J. G. Sijbrands
Oscar H. Franco
Moniek P. M. de Maat
Frank W. G. Leebeek
Abbas Dehghan
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 2/2017
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-4139-5

Other articles of this Issue 2/2017

Diabetologia 2/2017 Go to the issue